University of California, Berkeley   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Berkeley CA United States (1868)

Organization Overview

First Clinical Trial
1977
NCT00000492
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

California Cancer Consortium | Lawrence Berkeley National Laboratory | Lawrence Livermore National Laboratory at University of California | UC Berkeley | UC Berkeley and NBER | University of California | University of California at Berkeley | University of California, Berkeley | University of California, Davis, Dermatology | University of California, Davis - M.I.N.D. Institute | University of California, San Francisco Memory and Aging Center | University of California, San Francisco, USA

Active Ingredients

Drugs in Phase 4 Trials (6)

cabotegravir (Vocabria) (1 trial)

donepezil (aricept) (2 trials)

fentanyl (Innovar) (1 trial)

propylene glycol (1 trial)

silicone (1 trial)

varenicline (chantix) (1 trial)

Drugs in Phase 3 Trials (8)

atropine (2 trials)

chlorthalidone (Hygroton) (1 trial)

hydrochlorothiazide (esidrix) (1 trial)

metformin (glucophage) (1 trial)

methylprednisolone (medrol) (2 trials)

propranolol (inderal) (1 trial)

triamterene (dyrenium) (1 trial)

vitamin c (2 trials)

Drugs in Phase 2 Trials (15)

bevacizumab (avastin) (2 trials)

bortezomib (velcade) (1 trial)

carboplatin (paraplatin) (2 trials)

crispr_scd001 (1 trial)

dolutegravir (tivicay) (1 trial)

emtricitabine (emtriva) (1 trial)

fluorouracil (efudex) (1 trial)

gefitinib (iressa) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

lamivudine (epivir) (1 trial)

leucovorin (1 trial)

paclitaxel (taxol) (2 trials)

tenofovir (viread) (1 trial)

thalidomide (Thalomid) (1 trial)

vicriviroc (1 trial)

Drugs in Phase 1 Trials (10)

decitabine (dacogen) (1 trial)

deuterated water (1 trial)

diazoxide (hyperstat) (1 trial)

lenalidomide (revlimid) (1 trial)

n-(4-hydroxyphenyl)all-trans retinamide (2 trials)

nicotine (nicorette) (2 trials)

obinutuzumab (gazyva) (1 trial)

psilocybin (1 trial)

tirapazamine (1 trial)

tolcapone (tasmar) (4 trials)

Drugs in Other Trials (16)

41 ca (1 trial)

bovine lactoferrin (1 trial)

bromocriptine (parlodel) (1 trial)

calcium carbonate (1 trial)

entacapone (comtan) (1 trial)

levetiracetam (keppra) (1 trial)

methylcellulose (1 trial)

moringa (1 trial)

permethrin (nix) (1 trial)

povidone-iodine (betadine) (1 trial)

soybean (1 trial)

sulforaphane (1 trial)

vitamin e (1 trial)

water (1 trial)

yellow fever vaccine 17d strain (1 trial)

zinc (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 3)

Amblyopia (Phase 4)

Bipolar Disorder (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Cardiovascular Diseases (Phase 3)

Communicable Diseases (Phase 2)

Coronary Disease (Phase 3)

Death, Sudden (Phase 3)

Death, Sudden, Cardiac (Phase 3)

Disease (Phase 4)

Heart Arrest (Phase 3)

Heart Diseases (Phase 3)

Hemoptysis (Phase 2)

HIV Infections (Phase 2)

Hypertension (Phase 3)

Infections (Phase 2)

Inflammation (Phase 3)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 1)

Lung Diseases (Phase 3)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 1)

Multiple Myeloma (Phase 2)

Multiple Organ Failure (Phase 4)

Myelodysplastic Syndromes (Phase 1)

Myeloproliferative Disorders (Phase 1)

Myocardial Infarction (Phase 3)

Myocardial Ischemia (Phase 3)

Myopia (Phase 3)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 2)

Obesity (Phase 3)

Plasmacytoma (Phase 2)

Precancerous Conditions (Phase 1)

Preleukemia (Phase 1)

Psychotic Disorders (Phase 4)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Respiratory Tract Infections (Phase 2)

Schizophrenia (Phase 4)

Stomach Neoplasms (Phase 2)

Syndrome (Phase 3)

Tobacco Use Disorder (Phase 4)

Ventricular Fibrillation (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 47
  • # of Trial APIs: 55